The next “Living Well with Myeloma” Teleconference will focus on approaches to relapsed myeloma. IMF Chairman of the Board Dr. Brian G.M. Durie will discuss:

  • what treatments you should consider if your myeloma has relapsed, with a focus on the latest FDA-approved drugs.
  • how to individualize treatment based on a patient’s prior therapies, the length of the onset of relapse, FiSH genetic-risk status, age, and frailty score.
  • the latest clinical trials, in particular immune therapies.

You won’t want to miss this FREE IMF teleconference followed by a Q&A session! Save the date and register now!

REGISTER NOW


We thank our sponsors for supporting this educational program: 
Celgene, and Takeda Oncology

Previous Post
If a drug is not working in a current combination therapy, can it be used as part of another combination?
Next Post
What new drug options will be available for patients with relapsed and refractory multiple myeloma in 2020?

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt out, click for more information.